The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at ...

It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.